ArticleJournal of the American Heart Association2026
Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transsubclavian versus transfemoral TAVR with self-expanding valves.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve replacement using self-expandable valves requires permanent pacemaker implantation (PPI) more often compared with balloon-expandable systems. The Navitor prosthesis is a novel, tubular-shaped self-expandable valve with increasing use.
methodsThirty-day PPI rates were compared between 148 patients treated with the Navitor system and 165 patients treated with the Evolut system. Patients with preexisting PPI, high-risk ECG (right bundle-branch block), and Navitor 35-mm/Evolut 34-mm prostheses were excluded. Multivariable logistic regression was used to adjust for baseline differences.
resultsPatients treated with Navitor were older (83.0 [IQR, 78-86] versus 81.0 [IQR, 76-84] years;
conclusionsDepending on prosthesis size, transcatheter aortic valve replacement with the Navitor system may have PPI rates comparable to other self-expandable valves. High implantation of the Navitor may be attempted to reduce PPI rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.